Uppsala University

Notice to Annual General Meeting of shareholders in Loomis AB

Retrieved on: 
Wednesday, March 27, 2024

STOCKHOLM, March 27, 2024 /PRNewswire/ -- The shareholders of Loomis AB, Reg. No 556620-8095 ("Loomis" or the "company"), are hereby invited to participate in the annual general meeting (the "AGM") to be held on Monday May 6, 2024 at 5 p.m. CEST, in Grünewaldsalen at Stockholm Concert Hall, entrance Kungsgatan 43, Stockholm. Registration for the AGM begins at 4.30 p.m. CEST.

Key Points: 
  • A shareholder who wishes to attend the meeting venue in person or by proxy, must give notice of this in accordance with A) above.
  • Hence, a notice of participation only through postal voting is not sufficient for a person who wishes to attend the meeting venue.
  • The completed and signed postal voting form may be sent by post to Loomis AB, "AGM", c/o Euroclear Sweden AB, P.O.
  • She is a board member of Movestic Livförsäkring AB, Solid Försäkringsaktiebolag, Resurs Holding AB and Resurs Bank AB.

Focus on accelerating Finnish mine project as Eurobattery Minerals publishes Q4 report for 2023

Retrieved on: 
Wednesday, March 13, 2024

In October, Eurobattery Minerals announced that it will not renew its exploration licenses for its seven Swedish assets when the permits expire.

Key Points: 
  • In October, Eurobattery Minerals announced that it will not renew its exploration licenses for its seven Swedish assets when the permits expire.
  • The decision will enable Eurobattery Minerals to focus on projects which are in the more advanced stages to create better shareholder value.
  • In October, Eurobattery Minerals announced its partnership with the Research Center for Smart Exploration led by Uppsala University in Sweden.
  • This information is information that Eurobattery Minerals is obliged to make public pursuant to the EU Market Abuse Regulation.

Dr. Daniel Röshammar Joins InSilicoTrials as Vice President of Research & Development

Retrieved on: 
Monday, February 12, 2024

MILAN, Feb. 12, 2024 /PRNewswire/ -- InSilicoTrials is thrilled to announce the appointment of Dr. Daniel Röshammar as Vice President of Research & Development, marking a significant step forward in our mission to revolutionize healthcare through the power of in silico technology.

Key Points: 
  • MILAN, Feb. 12, 2024 /PRNewswire/ -- InSilicoTrials is thrilled to announce the appointment of Dr. Daniel Röshammar as Vice President of Research & Development, marking a significant step forward in our mission to revolutionize healthcare through the power of in silico technology.
  • With an illustrious career spanning various therapeutic areas, including cardiovascular diseases, infectious diseases, reproductive health, and oncology, Dr. Röshammar's boasts significant expertise in clinical drug development, clinical pharmacology, and pharmacometrics.
  • "Daniel's appointment is a testament to our commitment to leading the way in AI and simulation tools for drug development," said Luca Emili, CEO of InSilicoTrials.
  • In his capacity as Vice President of Research & Development at InSilicoTrials, Dr. Daniel Röshammar will harness his profound knowledge in pharmacometrics and model-informed drug development to directly oversee and innovate our R&D projects.

Dr. Daniel Röshammar Joins InSilicoTrials as Vice President of Research & Development

Retrieved on: 
Monday, February 12, 2024

MILAN, Feb. 12, 2024 /PRNewswire/ -- InSilicoTrials is thrilled to announce the appointment of Dr. Daniel Röshammar as Vice President of Research & Development, marking a significant step forward in our mission to revolutionize healthcare through the power of in silico technology.

Key Points: 
  • MILAN, Feb. 12, 2024 /PRNewswire/ -- InSilicoTrials is thrilled to announce the appointment of Dr. Daniel Röshammar as Vice President of Research & Development, marking a significant step forward in our mission to revolutionize healthcare through the power of in silico technology.
  • With an illustrious career spanning various therapeutic areas, including cardiovascular diseases, infectious diseases, reproductive health, and oncology, Dr. Röshammar's boasts significant expertise in clinical drug development, clinical pharmacology, and pharmacometrics.
  • "Daniel's appointment is a testament to our commitment to leading the way in AI and simulation tools for drug development," said Luca Emili, CEO of InSilicoTrials.
  • In his capacity as Vice President of Research & Development at InSilicoTrials, Dr. Daniel Röshammar will harness his profound knowledge in pharmacometrics and model-informed drug development to directly oversee and innovate our R&D projects.

Alvarez & Marsal Expands Its Capital Markets & Accounting Advisory Senior Talent Globally

Retrieved on: 
Tuesday, January 30, 2024

Leading global professional services firm Alvarez & Marsal (A&M) announced the appointment of Stockholm-based Annika Melin Jakobsson and New York-based Patricia Alonso de la Fuente as Global Transaction Advisory Group (TAG) Managing Directors within its Capital Markets & Accounting Advisory (CMAA) practice.

Key Points: 
  • Leading global professional services firm Alvarez & Marsal (A&M) announced the appointment of Stockholm-based Annika Melin Jakobsson and New York-based Patricia Alonso de la Fuente as Global Transaction Advisory Group (TAG) Managing Directors within its Capital Markets & Accounting Advisory (CMAA) practice.
  • Ms. Melin Jakobsson ensures clients’ IPO readiness, and once listed, their alignment with capital markets’ governance, risk and compliance and financial reporting requirements.
  • She focuses on IPOs, acquisitions, divestitures, international financial reporting standards (IFRS), US generally accepted accounting principles (GAAP) conversions and complex technical accounting matters.
  • Prior to joining A&M, Ms. Alonso de la Fuente served with KPMG, most recently as Partner in Deal Advisory in New York, along with leading that firm’s Capital Markets and Accounting Advisory Services US-LatAm corridor.

MitoSense Inc. and Uppsala University, in Collaboration with Elliott Mitochondrial Center and Sallie Astor Burdine Breast Foundation, Announce Breakthrough in Mitochondrial Preservation

Retrieved on: 
Thursday, January 25, 2024

This method, utilizing extracellular vesicles from mesenchymal stromal cells (imEVs), marks a significant advancement in mitochondrial medicine.

Key Points: 
  • This method, utilizing extracellular vesicles from mesenchymal stromal cells (imEVs), marks a significant advancement in mitochondrial medicine.
  • Karl-Henrik Grinnemo and Sergey Rodin of Uppsala University, vital contributors to this research, described the study as a "milestone in mitochondrial science."
  • "The partnership with Elliott Mitochondrial Center and the Sallie Astor Burdine Breast Foundation has been instrumental in this discovery, reflecting our collective commitment to pioneering medical solutions," he stated.
  • This collaborative effort represents a major addition to MitoSense Inc.'s achievements, highlighting the company's crucial role in advancing medical science and enhancing patient care.

MitoSense Inc. and Uppsala University, in Collaboration with Elliott Mitochondrial Center and Sallie Astor Burdine Breast Foundation, Announce Breakthrough in Mitochondrial Preservation

Retrieved on: 
Thursday, January 25, 2024

This method, utilizing extracellular vesicles from mesenchymal stromal cells (imEVs), marks a significant advancement in mitochondrial medicine.

Key Points: 
  • This method, utilizing extracellular vesicles from mesenchymal stromal cells (imEVs), marks a significant advancement in mitochondrial medicine.
  • Karl-Henrik Grinnemo and Sergey Rodin of Uppsala University, vital contributors to this research, described the study as a "milestone in mitochondrial science."
  • "The partnership with Elliott Mitochondrial Center and the Sallie Astor Burdine Breast Foundation has been instrumental in this discovery, reflecting our collective commitment to pioneering medical solutions," he stated.
  • This collaborative effort represents a major addition to MitoSense Inc.'s achievements, highlighting the company's crucial role in advancing medical science and enhancing patient care.

EQS-News: Expertise and continuity for HHLA's Executive Board

Retrieved on: 
Wednesday, January 17, 2024

Hamburger Hafen und Logistik AG (HHLA) has appointed a new member to its Executive Board for the Finance and Real Estate divisions.

Key Points: 
  • Hamburger Hafen und Logistik AG (HHLA) has appointed a new member to its Executive Board for the Finance and Real Estate divisions.
  • With these personnel decisions, the Supervisory Board of HHLA is strengthening the company by appointing experienced managers to two Management Board positions.
  • The Supervisory Board has appointed Annette Walter to the Executive Board of HHLA.
  • She has been a member of HHLA's Executive Board since 1 October 2016.

The strange story of the grave of Copernicus

Retrieved on: 
Wednesday, January 3, 2024

Nicholas Copernicus was the astronomer who, five centuries ago, explained that Earth revolves around the Sun, rather than vice versa. A true Renaissance man, he also practised as a mathematician, engineer, author, economic theorist and medical doctor. Upon his death in 1543 in Frombork, Poland, Copernicus was buried in the local cathedral. Over the subsequent centuries, the location of his grave was lost to history.Who was Copernicus?After his father’s death, Copernicus’s uncle assumed responsibility for his education.

Key Points: 


Nicholas Copernicus was the astronomer who, five centuries ago, explained that Earth revolves around the Sun, rather than vice versa. A true Renaissance man, he also practised as a mathematician, engineer, author, economic theorist and medical doctor. Upon his death in 1543 in Frombork, Poland, Copernicus was buried in the local cathedral. Over the subsequent centuries, the location of his grave was lost to history.

Who was Copernicus?

  • After his father’s death, Copernicus’s uncle assumed responsibility for his education.
  • The young scholar initially studied at the University of Kraków between 1491 and 1494, and later at Italian universities in Bologna, Padua and Ferrara.
  • In 1519, Copernicus also introduced the concept now known as Gresham’s law, a monetary principle addressing the circulation and valuation of money.

The Copernican model of the universe

  • The cornerstone of Copernicus’s contributions to science was his revolutionary model of the universe.
  • Contrary to the prevailing Ptolemaic model, which maintained that Earth was the stationary centre of the universe, Copernicus argued that Earth and other planets revolve around the Sun.

The search for Copernicus


The Frombork Cathedral serves as the final resting place of more than 100 people, most of whom lie in unnamed graves. There were several unsuccessful attempts to locate Copernicus’s remains, dating as far back as the 16th and 17th centuries. Another failed attempt was made by the French emperor Napoleon after the 1807 Battle of Eylau. Napoleon held Copernicus in high regard as a polymath, mathematician and astronomer.

  • They were guided by the theory of historian Jerzy Sikorski, who claimed that Copernicus, serving as the Canon of Frombork Cathedral, would have been buried near the cathedral altar for which he was responsible during his tenure.
  • This particular skeleton was identified as the closest match to that of Copernicus.

Forensic science

  • In addition to morphological studies, DNA analysis is often used for the identification of historical or ancient remains.
  • In the case of the presumed remains of Copernicus, a genetic identification was possible due to the well-preserved state of the teeth.

An unlikely find

  • An astronomical reference book used by Copernicus for many years was found to contain hair among its pages.
  • This book had been taken to Sweden as war booty following the Swedish invasion of Poland in the mid-17th century.
  • A meticulous examination of the book revealed several hairs, thought likely to belong to the book’s primary user, Copernicus himself.


Darius von Guttner Sporzynski does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Faron Pharmaceuticals Announces Board Changes

Retrieved on: 
Friday, September 22, 2023

Dr. Marie-Louise Fjällskog is a professional with extensive experience in the pharmaceutical and biopharmaceutical industry, particularly in the field of clinical oncology, translational research, and drug development.

Key Points: 
  • Dr. Marie-Louise Fjällskog is a professional with extensive experience in the pharmaceutical and biopharmaceutical industry, particularly in the field of clinical oncology, translational research, and drug development.
  • Her extensive expertise and leadership have also earned her a position on the board of Biovica International AB, a prominent biotech company in Sweden and in the US, respectively.
  • She is also on the board of Norwegian company Lytix Biopharma.
  • In January 2022, Dr. Fjällskog assumed the role of Chief Medical Officer at Faron where she lead Faron's clinical development programs, particularly the bexmarilimab program.